A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics

Despite the growing threat of antimicrobial resistance, pharmaceutical and biotechnology firms are reluctant to develop novel antibiotics because of a host of market failures. This problem is complicated by public health goals that demand antibiotic conservation and equitable patient access. Thus, a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antibiotics 2016-02, Vol.69 (2), p.73-88
Main Authors: Renwick, Matthew J, Brogan, David M, Mossialos, Elias
Format: Article
Language:English
Subjects:
692/308/153
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - isolation & purification
Anti-Bacterial Agents - pharmacology
Antibiotics
Bacteriology
Biomedical and Life Sciences
Bioorganic Chemistry
Biotechnology
Decision Support Techniques
Drug Discovery - methods
Drug Discovery - trends
Global Health
Health Policy
Humans
Life Sciences
Medicinal Chemistry
Microbiology
Motivation
Organic Chemistry
Public health
Review
review-article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the growing threat of antimicrobial resistance, pharmaceutical and biotechnology firms are reluctant to develop novel antibiotics because of a host of market failures. This problem is complicated by public health goals that demand antibiotic conservation and equitable patient access. Thus, an innovative incentive strategy is needed to encourage sustainable investment in antibiotics. This systematic review consolidates, classifies and critically assesses a total of 47 proposed incentives. Given the large number of possible strategies, a decision framework is presented to assist with the selection of incentives. This framework focuses on addressing market failures that result in limited investment, public health priorities regarding antibiotic stewardship and patient access, and implementation constraints and operational realities. The flexible nature of this framework allows policy makers to tailor an antibiotic incentive package that suits a country’s health system structure and needs.
ISSN:0021-8820
1881-1469
DOI:10.1038/ja.2015.98